## Management of Thyrotoxicosis in Pregnancy ### Clinical Context: Recurrent Graves' After RAI **Key Point:** Despite prior RAI treatment and euthyroid status, **high-titer TRAb can cross the placenta and cause fetal thyrotoxicosis and neonatal Graves' disease**. This patient's symptoms and elevated free T4 indicate **recurrent Graves' thyrotoxicosis**, not residual hypothyroidism from RAI. ### Why This Is Thyrotoxicosis, Not Hypothyroidism | Parameter | Finding | Interpretation | |-----------|---------|----------------| | **Free T4** | 14 pg/dL (normal 8–11) | **Elevated** — not low | | **Free T3** | 4.8 pg/dL (normal 2.3–4.2) | **Elevated** — not low | | **TSH** | 0.05 (suppressed) | Appropriate suppression to elevated T4 | | **TRAb** | High titer (8.5) | Active TSH receptor stimulation | | **Clinical symptoms** | Palpitations, tremor, anxiety | Consistent with thyrotoxicosis | **Clinical Pearl:** This is **recurrent Graves' disease** (not hypothyroidism from RAI). The high-titer TRAb indicate ongoing autoimmune activity despite prior RAI ablation. RAI does not eliminate the autoimmune process. ### Pregnancy-Specific Management Principles **High-Yield:** Antithyroid drugs in pregnancy have a critical risk–benefit profile: 1. **PTU (propylthiouracil)** is the drug of choice in the **first trimester** because: - Minimal placental transfer (highly protein-bound) - No association with methimazole embryopathy (methimazole causes rare but serious birth defects: esophageal atresia, choanal atresia) - Inhibits T4→T3 conversion (additional benefit in thyroid storm) 2. **Methimazole** can be used after the first trimester if needed (lower risk of PTU hepatotoxicity with long-term use) 3. **Beta-blockers** (e.g., propranolol) provide symptom relief but do NOT treat the underlying thyrotoxicosis ### Fetal and Neonatal Risks **Warning:** High-titer TRAb (>5 IU/L) can: - Cross the placenta in the second and third trimesters - Stimulate fetal thyroid → fetal thyrotoxicosis - Cause fetal tachycardia, intrauterine growth restriction, preterm labor - Result in **neonatal Graves' disease** (transient, lasting 1–3 months as maternal antibodies clear) **Mnemonic: FETAL GRAVES** — Fetal tachycardia, Exophthalmos (rare), Thyroid enlargement, Accelerated bone maturation, Low birth weight; Growth restriction, Respiratory distress, Arrhythmias, Vomiting, Exaggerated startle, Signs of hyperthyroidism. ### Recommended Management **Step 1:** Start **PTU** immediately (first-line in first trimester) - Target TSH: 0.5–2.0 mIU/L (slightly higher than non-pregnant range to minimize fetal hypothyroidism risk) - Typical starting dose: 100–150 mg three times daily - Monitor TSH and free T4 every 4–6 weeks **Step 2:** Add **propranolol** for symptom control (palpitations, tremor, anxiety) - Dose: 20–40 mg three times daily - Safe in pregnancy; crosses placenta minimally **Step 3:** Monitor TRAb titer in second and third trimesters - If TRAb remain high, consider fetal ultrasound for signs of thyrotoxicosis **Step 4:** Plan for postpartum management - PTU can be continued during breastfeeding (minimal milk transfer) - Neonatal screening for TRAb and signs of thyrotoxicosis ### Why Other Options Are Incorrect **Option A (Propranolol alone, avoid antithyroid drugs):** Propranolol treats symptoms but does NOT reduce thyroid hormone synthesis. Untreated maternal thyrotoxicosis and high-titer TRAb expose the fetus to significant risk. Antithyroid drugs are NOT contraindicated in pregnancy; PTU is safe and indicated. **Option C (Ultrasound and FNA):** There is no clinical suspicion of malignancy. This is recurrent autoimmune thyrotoxicosis, not a nodular lesion. Unnecessary testing delays treatment. **Option D (Reassure and observe):** High-titer TRAb in pregnancy REQUIRE treatment to prevent fetal thyrotoxicosis and neonatal Graves' disease. Observation is dangerous.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.